Clinical Impact of BK Virus Surveillance on Outcomes in Kidney Transplant Recipients

Abstract

BackgroundThe objective of this study was to investigate the clinical impact of BK virus surveillance on graft injury in kidney transplantation. MethodsBK viremia in kidney transplant recipients was evaluated by use of plasma quantitative polymerase chain reaction. The prevalence of BK viremia and BK virus–associated nephropathy (BKVAN) and the clinical impact of BK viremia on graft outcomes were assessed. ResultsThis study took place between January 2008 and June 2013. A total of 213 kidney transplant recipients were included. The prevalence of BK viremia and high BK viremia (≥1 × 104 copies/mL) was 66.7% (142/213) and 17.4% (37/213), respectively. A diagnosis of BKVAN was confirmed by means of allograft biopsy in 9 patients (4.2%). The estimated glomerular filtration rate after transplantation was similar in both the low BK viremia (<1 × 104 copies/mL) and non–BK viremia groups but was significantly lower in the high BK viremia group after 18 months. In receiver operating characteristic curve analysis, the area under the curve value of plasma polymerase chain reaction was 0.980. We found that a viral load >92,850 copies/mL was able to predict BKVAN with 89% sensitivity and 94.6% specificity. The risk factors for viral loads ≥1 × 104 copies/mL were cytomegalovirus infection, steroid pulse therapy, and acute rejection. ConclusionsHigh BK viremia was associated with poor graft function after kidney transplantation. The serial monitoring of BK viremia in kidney transplant recipients was helpful in predicting BKVAN and might prevent further progression.